Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(43%)
Terminated
1(14%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_3
3
43%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
Not yet recruiting2
Active, not recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 22 (28.6%)
Phase 33 (42.9%)

Trials by Status

active_not_recruiting114%
recruiting229%
not_yet_recruiting229%
unknown114%
terminated114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_2

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

NCT07646145
not_yet_recruitingphase_1

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

NCT07487168
active_not_recruitingphase_3

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185
not_yet_recruitingphase_2

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

NCT07189793
recruitingphase_3

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

NCT06696794
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07646145Phase 2

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Recruiting
NCT07487168Phase 1

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

Not Yet Recruiting
NCT04241185Phase 3

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Active Not Recruiting
NCT07189793Phase 2

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Not Yet Recruiting
NCT06696794Phase 3

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Recruiting
NCT00974818Phase 3

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Terminated
NCT00893490Phase 1

Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7